Michael J. Yang — Chief Commercial Officer and Executive Vice President at ACADIA Pharmaceuticals

Mr. Michael J. Yang has been Chief Commercial Officer and Executive Vice President of ACADIA Pharmaceuticals Inc. since March 30, 2017. Mr. Yang is a seasoned executive with extensive expertise in successfully launching and growing major pharmaceutical products across a number of therapeutic areas, including CNS. His patient-centric approach, proven leadership skills and focus on innovation of great value to the ongoing commercialization of NUPLAZID in Parkinson's disease psychosis and its potential expansion into other areas of large unmet need. Mr. Yang is a Member of ACADIA's executive team. Mr. Yang joined ACADIA from Janssen Pharmaceutical Companies of Johnson & Johnson, where he served as President of Janssen Biotech Inc. and was responsible for building Janssen's U.S. Immunology business, generating more than $8 billion in annual revenues. Mr. Yang began his career at Johnson & Johnson in 1997 and held numerous senior commercial positions such as President, CNS where he was responsible for growing the anti-psychotic long-acting therapy portfolio. His broad background of commercialization and general management experience also includes roles as the Worldwide General Manager of the Medical Device companies of Therakos, Inc and Veridex, LLC, where he launched new platforms, expanded global revenues and diversified the product lines. Prior to that, Mr. Yang served as Vice President of Sales and Marketing, Oncology at Ortho Biotech Inc. Mr. Yang earned his Bachelor of Science degree in Business Administration, Marketing from San Diego State University.